Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 2 to 12

Comparing MTA and Biodentine for treating children's teeth

Official title: Clinical and Radiographic Success of Mineral Trioxide Aggregate (MTA) vs Septodont Biodentine in Primary Molars in Pulpotomy and Indirect Pulp Cap Treatments

Run by Geisinger Clinic · NCT04863222 · Data updated 2026-11-12

This study is testing whether two different treatments for children's tooth issues, MTA and Biodentine, work better for saving baby teeth in kids aged 2 to 12.

Quick facts

PhasePhase 4
Study typeInterventional
Ages2 Years to 12 Years
SexAll
Enrollment646 (estimated)
SponsorGeisinger Clinic
Academic / other
Locations1 site (Danville, Pennsylvania)
StatusRecruiting
StartedNovember 12, 2021
Main results expectedAugust 1, 2026
Study endsDecember 1, 2026
Registry record updatedDecember 23, 2025
Trial IDNCT04863222 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 2 to 12 with bilateral symptomatic or asymptomatic vital primary molars requiring pulpotomy or indirect pulp cap treatments.

Probably not a fit

Patients with irreversible pulpitis, necrotic pulp, or non-restorable molars will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective interventional study aims to evaluate the clinical and radiographic success of two medicaments, mineral trioxide aggregate (MTA) and Biodentine, in vital pulp therapy for primary molars in children aged 2 to 12. The study employs a randomized split-mouth design, where each child will receive one treatment on one side of their mouth and the other treatment on the opposite side. Participants will be monitored for clinical and radiographic outcomes every six months for three years following the procedures. The research is conducted in accordance with the standards set by the American Academy of Pediatric Dentistry at Geisinger Medical Center and Geisinger Bloomsburg Hospital.

Why it matters

Potential benefit: If successful, this study could provide a more cost-effective and less discoloring alternative to MTA for vital pulp therapy in children.

How similar studies have gone: While there is limited research on Biodentine, the study's approach of comparing it with MTA in pediatric dental care is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female patients ages of 2 to ≤12 years.
* Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.
* Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more quadrants.
* Parents of patients who can provide consent in English.
* Patients who need treatment in an operating room setting at Geisinger.

Exclusion Criteria:

* Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.
* Radiographs not displaying furcation region of the tooth.
* Patients with cardiac conditions who need prophylaxis for infective Endocarditis.
* Patients with any type of cancer in the past or present.
* Non-restorable molars.

Where it's running

  • Geisinger
    Danville, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.